Global patient monitoring market worth more than $31B

The global advanced patient monitoring market is currently worth about $31.4 billion, inclusive of devices, peripherals, software, packaged services and other applications, according to a report from Kalorama Information. 

The market has benefited from the demand to move to a more wireless and streamlined operation both within major health facilities and in the home treatment markets. Kalorama's report, Advanced Remote Patient Monitoring Systems, in its eighth edition, is a comprehensive study on the patient monitoring industry, including patient monitoring equipment and devices that have advanced features.

"Cost savings are the major driver of sales, but the demand to integrate data into an EMR has also helped fuel purchases of new PM systems," said Bruce Carlson, publisher of Kalorama Information. "There is also an increasing trend to upgrade to ambulatory and handheld devices."

The global advanced patient monitoring market has continued its expansion in both the institutional and home segments of the health market with the United States and many European countries leading in implementation. The advanced patient monitoring market includes products in blood management and function monitors, cardiac event and function monitors, neurological event monitors, respiratory function monitors, and other advanced monitors.

 
Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.